研究单位：[1]Shanghai Zhongshan Hospital[2]Changhai Hospital[3]Shanghai 10th People's Hospital[4]First Affiliated Hospital of Zhejiang University[5]The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School[6]Fujian Cancer Hospital[7]First Affiliated Hospital of Fujian Medical University[8]Zhongshan Hospital Xiamen University[9]West China Hospital[10]Peking University Cancer Hospital & Institute[11]Xinqiao Hospital of Chongqing[12]309th Hospital of Chinese People's Liberation Army[13]Heilongjiang Provincial Agricultural Reclamation General Hospital[14]Longyan First Hospital, Affiliated to Fujian Medical University[15]Peking University First Hospital[16]The Third Affiliated Hospital of Qiqihar Medical Universitiy[17]Anhui Provincial Hospital[18]First Affiliated Hospital of Xinjiang Medical University[19]Qingdao University[20]The 4th people's hospital of Wuxi City, Affiliated to Jiangnan University[21]Subei People's Hospital of Jiangsu Province,Yangzhou University[22]The Affiliated Zhongshan Hospital of Dalian University[23]Jilin University[24]First Affiliated Hospital of Guangxi Medical University[25]Fudan University[26]Shanghai East Hospital,Tongji University School of Medicine[27]Chinese PLA General Hospital[28]The 4th People's Hospital of Linfen City[29]Nanfang Hospital of Southern Medical University[30]Yunnan Cancer Hospital[31]Shandong Cancer Hospital and Institute[32]Sichuan Cancer Hospital and Research Institute[33]First Affiliated Hospital, Sun Yat-Sen University[34]The Second Affiliated Hospital of Chongqing Medical University[35]Fujian Medical University Union Hospital[36]The People's Hospital of Hunan Province
This clinical trial is a prospective, randomized, controlled and multicenter study.And the trial is going to better control intrahepatic tumors for hepatocellular carcinoma(HCC) patients who meet the inclusion criterion.The patients were divided into two groups, the group A by TACE and the other group B by external- beam radiotherapy(EBRT) after 2 times TACE. Then the therapeutic effects and toxicities of TACE and EBRT are evaluated during the follow-up period. The study design plans to enroll 300 patients, and each group includes 150 cases.
